Fidelity Investments
IRD

Fidelity Investments’s Opus Genetics IRD Stock Holding History

Fidelity Investments’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36 Buy
+8
New +$28 ﹤0.01% 5316
2025
Q1 		– Sell
-1
Closed -$1 – 5762
2024
Q4 		$1 Buy
+1
New +$1 ﹤0.01% 5518
2023
Q3 		– Sell
-100
Closed -$434 – 5561
2023
Q2 		$434 Buy
+100
New +$475 ﹤0.01% 4830

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments's IRD Position: Q1 2026 in Review

Fidelity Investments opened a new position in Opus Genetics (IRD) in Q1 2026: 8 shares worth $36. The stake represents ﹤0.01% of the portfolio and ranks #5316 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in IRD as recently as Q4 2024.

Fidelity Investments first reported a position in IRD in Q2 2023 and has held it in 3 quarters since. The position peaked at $434 in Q2 2023. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Fidelity Investments held 8 shares of Opus Genetics worth $36 as of Q1 2026.
  • Opus Genetics was a new Fidelity Investments position in Q1 2026.
  • Opus Genetics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5316 holding.
  • Fidelity Investments first reported a position in Opus Genetics in Q2 2023 and has held it in 3 quarters since.
  • Fidelity Investments's Opus Genetics position peaked at $434 in Q2 2023.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.